市場調査レポート
商品コード
1147336
慢性的嗅覚・味覚消失市場 - 市場の洞察、疫学、市場予測:2032年Chronic Smell and Flavor Loss - Market Insight, Epidemiology And Market Forecast - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
慢性的嗅覚・味覚消失市場 - 市場の洞察、疫学、市場予測:2032年 |
出版日: 2022年11月01日
発行: DelveInsight
ページ情報: 英文 141 Pages
納期: 1~3営業日
|
主要7ヶ国における慢性的嗅覚・味覚消失の市場規模は、2021年に2億1,400万米ドルとなりました。同市場は今後もさらに拡大すると予測されています。
当レポートでは、主要7ヶ国における慢性的嗅覚・味覚消失市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。
DelveInsight's 'Chronic smell and flavor loss - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of chronic smell and flavor loss, historical and forecasted epidemiology, as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The chronic smell and flavor loss market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted chronic smell and flavor loss symptoms market size from 2019 to 2032, segmented by seven major markets. The report also covers current chronic smell and flavor loss symptoms treatment practice/algorithms, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.
Study Period: 2019-2032.
Disorders of smell and taste challenge the ability to consume safe and healthy diets as well as enjoy eating and food-related behaviors. These disorders impair the ability to sense warning odors in foods and the environment and hinder the quality of life (QoL)-related to social interactions, eating, and feelings of well-being. These are not life-threatening and usually represent significant underlying diseases; therefore, they are often overlooked by the medical community.
It covers the details of conventional and current medical therapies and diagnoses available in the Chronic smell and flavor loss market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Chronic smell and flavor loss market report thoroughly understands Chronic smell and flavor loss symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides chronic smell and flavor loss treatment algorithms and treatment guidelines for chronic smell and flavor loss symptoms in the US, Europe, and Japan.
There are only limited treatments available for smell disorders, and proven effective treatment is only available where nasal illnesses cause smell disorders. The focus is on surgical treatment (polypectomy, pansinus procedures) and the application of corticosteroids. Regarding surgical and non-surgical treatments, the so-called olfactory cleft disease is particularly difficult to treat; this involves isolated swelling in the olfactory cleft area.
A few major unmet needs in the market include maintaining a balance between pain relief and side effects, lack of standardized tools to assess functional impairment, gaps in proper diagnosis and understanding, challenging diagnosis, absence of pain biomarkers, misperception and limited knowledge and lack of individualized treatment
The Chronic smell and flavor loss symptoms epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and its trends and assumptions.
The total prevalent cases of Chronic smell and flavor loss patients in the 7MM will increase during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Chronic smell and flavor loss symptoms epidemiology segmented as the total prevalent cases of chronic smell and flavor loss, total diagnosed cases of chronic smell and flavor loss (including COVID-19 patients), age-specific cases of chronic smell and flavor loss, and etiology-specific cases of Chronic smell and flavor loss. The report includes the prevalent cases scenario of Chronic smell and flavor loss in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the Chronic smell and flavor loss epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The prevalent cases of Chronic smell and flavor loss associated in 7MM countries were around 214 million in 2021.
The Chronic smell and flavor loss report's drug chapter segment encloses the detailed analysis of Chronic smell and flavor loss early-stage (Phase II and III) pipeline drugs. It also helps understand the Chronic smell and flavor loss clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Cyrano Therapeutics has developed a nasal spray to treat and restore the sense of smell and flavor in those who have experienced a chronic loss of those senses. The composition comprises phosphodiesterase (PDE) inhibitors formulated for intranasal administration. The major mechanism underlying all pathologies responsible for smell and flavor loss is similar. It involves inhibition of stem cell activation, which normally occurs by the action of adenylyl cyclase III through cAMP and cGMP.
The report's Chronic smell and flavor loss market outlook helps understand the historic, current, and forecasted Chronic smell and flavor loss market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the Chronic smell and flavor loss market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.
According to DelveInsight, the chronic smell and flavor loss market in the 7MM is expected to grow steadily during the study period 2019-2032.
There are only limited treatments available for smell disorders, and proven effective treatment is only available where nasal illnesses cause smell disorders. The focus is on surgical treatment (polypectomy, pansinus procedures) and the application of corticosteroids. Regarding surgical and non-surgical treatments, the so-called olfactory cleft disease is particularly difficult to treat; this involves isolated swelling in the olfactory cleft area. Concerning the treatment of other non-sinonasal smell disorders, treatments, which are not proven to be efficient include treatment with estrogens, zinc, minocycline, and vitamin A at 10,000 i.e., oral over 4 weeks.
Treatments with corticoids and vitamin A are often attempted, but there is a lack of convincing clinical studies. The same applies to studies involving acupuncture. Only for zinc gluconate (140 mg/day for 3 months) is data available on the therapeutic effectiveness in idiopathic dysgeusia. For BMS, tricyclic antidepressants (amitriptyline, imipramine) improve the abnormal sensation. Successful treatments have also been carried out with clonazepam or diazepam; gabapentin appears ineffective.
This section includes a glimpse of the Chronic smell and flavor loss market in the 7MM.
The Chronic smell and flavor loss market size in the seven major markets was approximately USD 2.8 billion in 2021.
This section provides the total chronic smell and flavor loss market size and market size by therapies in the United States.
The United States accounts for the largest market size of chronic smell and flavor loss compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
The total chronic smell and flavor loss market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total chronic smell and flavor loss market size and market size by therapies in Japan are also mentioned.
This section focuses on the uptake of the potential drugs recently launched or expected to be launched in the market during 2019-2032. The analysis covers the chronic smell and flavor loss market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Chronic smell and flavor loss key players involved in developing targeted therapeutics.
Major market players include Cyrano Therapeutics, among others.
The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Chronic smell and flavor loss emerging therapies.
Proactively approaching reimbursement can positively impact both during the early stages of product development and after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select markets with better market access can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SMEs' opinions working in the chronic smell and flavor loss domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or chronic smell and flavor loss market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
We perform a Competitive and Market Intelligence analysis of the chronic smell and flavor loss Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.